Bioequivalence study of BHV-0223 in patients with amyotrophic lateral sclerosis

Trial Profile

Bioequivalence study of BHV-0223 in patients with amyotrophic lateral sclerosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs Riluzole (Primary) ; Riluzole
  • Indications Amyotrophic lateral sclerosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Jan 2018 According to a Biohaven Pharmaceutical Holding Company, based on the results, the company plans to submit a new drug application (NDA) requesting BHV-0223 to be approved in the first half of 2018.
    • 09 Jan 2018 Top-line results (n=138) published in a Biohaven Pharmaceutical Holding Company media release.
    • 06 Nov 2017 According to a Biohaven Pharmaceuticals media release, company today announced that the first subject was dosed in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top